The thought on everyone's mind when looking at Amarin (AMRN -1.92%) as an investor right now is: What approach is the company going to take in commercializing its new hypertriglyceridemia drug, Vascepa? Many people consider the company a potential acquisition target; others thought it would seek a partnership before going forward. But after the release of yesterday's conference call, the evidence might suggest that it plans to commercialize Vascepa on its own, an option that previously had some investors a little apprehensive. Motley Fool health care analyst Max Macaluso talks in this video about his take on Amarin's strategy going forward and why the CEO's words were well-received by the market.